Publicaciones - Neurociencia Clínica y Experimental

Cargando...

Costa T, Fernandez-Villalba E, Izura V, Lucas-Ochoa AM, Menezes-Filho NJ, Santana RC, de Oliveira MD, Araújo FM, Estrada C, Silva V, Costa SL, Herrero MT. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. J Neuroimmune Pharmacol. 2021 Jun;16(2):390-402. doi: 10.1007/s11481-020-09925-8. Epub 2020 Jun 21. PubMed PMID: 32564332.

AÑO: 2021; IF: 7.285

32564332

Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. PubMed PMID: 34418400; PubMed Central PMCID: PMC8434816.

AÑO: 2021; IF: 59.935

34418400

Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, Berenguer-Ruiz L, Candeliere Merlicco A, Martinez-Navarro ML, Gracia Gil J, Romero-Sanchez CM, Alfaro-Saez A, Diaz I, Gimenez-Martinez J, Mendez-Miralles MA, Millan-Pascual J, Jimenez-Pancho J, Mola S, Sempere AP. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021 Feb;8(2):385-394. doi: 10.1002/acn3.51282. Epub 2020 Dec 25. PubMed PMID: 33369288; PubMed Central PMCID: PMC7886031.

AÑO: 2021; IF: 5.43

33369288

Tadiri CP, Gisinger T, Kautzky-Willer A, Kublickiene K, Herrero MT, Norris CM, Raparelli V, Pilote L; GOING-FWD Consortium. Determinants of perceived health and unmet healthcare needs in universal healthcare systems with high gender equality. BMC Public Health. 2021 Jul 31;21(1):1488. doi: 10.1186/s12889-021-11531-z. PubMed PMID: 34332567; PubMed Central PMCID: PMC8325202.

AÑO: 2021; IF: 4.135

34332567

Meca-Lallana J, García-Merino JA, Martínez-Yélamos S, Vidal-Jordana A, Costa L, Eichau S, Rovira À, Brieva L, Agüera E, Zarranz AR. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegener Dis Manag. 2021 Jun;11(3):251-261. doi: 10.2217/nmt-2020-0049. Epub 2021 May 10. Review. PubMed PMID: 33966475.

AÑO: 2021

33966475

< Anterior Siguiente >

Publicaciones - Neurociencia Clínica y Experimental

Instituto de Investigación Sanitaria Acreditado

Neurociencia Clínica y Experimental